title: Extended treatment with brentuximab vedotin in patients with relapsed or refractory CD30-positive hematological malignancies.
authors.affiliation: University of Alabama at Birmingham , Birmingham, AL , USA.
authors.forename: Andres
authors.initials: A
authors.lastname: Forero-Torres
authors.forename: Nancy L
authors.initials: NL
authors.lastname: Bartlett
authors.forename: Robert B
authors.initials: RB
authors.lastname: Berryman
authors.forename: Robert
authors.initials: R
authors.lastname: Chen
authors.forename: Jeffrey V
authors.initials: JV
authors.lastname: Matous
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Fanale
authors.forename: Owen A
authors.initials: OA
authors.lastname: O'Connor
authors.forename: Randal
authors.initials: R
authors.lastname: Olshefski
authors.forename: Scott E
authors.initials: SE
authors.lastname: Smith
authors.forename: Dirk
authors.initials: D
authors.lastname: Huebner
authors.forename: Pamela L
authors.initials: PL
authors.lastname: Levine
authors.forename: Laurie E
authors.initials: LE
authors.lastname: Grove
authors.forename: Ajay K
authors.initials: AK
authors.lastname: Gopal
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000079963:Brentuximab Vedotin; D004334:Drug Administration Schedule; D019008:Drug Resistance, Neoplasm; D005221:Fatigue / Q000139:chemically induced; D005260:Female; D006261:Headache / Q000139:chemically induced; D019337:Hematologic Neoplasms / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D018796:Immunoconjugates / Q000009:adverse effects / Q000627:therapeutic use*; D007239:Infections / Q000139:chemically induced; D017730:Ki-1 Antigen / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000139:chemically induced; D012008:Recurrence; D013035:Spasm / Q000139:chemically induced; D055815:Young Adult
chemical_list: D018796:Immunoconjugates; D017730:Ki-1 Antigen; D000079963:Brentuximab Vedotin